Label Expansion Opportunity: seeking approval of Auryxia for the treatment of patients with iron deficiency anemia and non-dialysis dependent chronic kidney disease
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
